Skip to content
MarketScale
‹ Back to IndustriesHealthcare

From Content Scramble to Streamlined Success: Demystifying Modular Content in Life Sciences

Life sciences teams are turning to modular content to cut production time and improve compliance and personalization. In a podcast episode hosted by Annalise Ludtke, experts discuss the strategic nature of modular content, challenges in its implementation, and strategies for successful adoption. Key topics include defining modular content, overcoming regulatory hurdles, and the importance of change readiness.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Annalise Ludtke · Alana GoodmanContent Creation and ManagementDecisive ConsultingLife Sciences Sector
Share
From Content Scramble to Streamlined Success: Demystifying Modular Content in Life Sciences

Key takeaways

01

Modular content is a strategic approach to streamline content creation in life sciences.

02

Regulatory and operational challenges are major hurdles in adopting modular content.

03

Successful adoption requires a robust digital asset management system and change readiness.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Modular content is the latest buzz in the life sciences industry, offering a strategic way to streamline content creation and management. With promises of increased efficiency and personalized outreach, many organizations are eager to jump on the bandwagon. But is it truly worth the effort?

What exactly is modular content, and how can life science organizations leverage it effectively?

Welcome to “Amend & Progress,” Vodori’s podcast dedicated to exploring promotional material review processes. In this episode, Annalise Ludtke hosts a discussion on modular content with Alana Goodman, Program and Operations Lead at Decisive Consulting, and Stephanie Taubin, founder and CEO at Taubin Collaborative Solutions. They explore the nuances of modular content, its challenges, and strategies for successful adoption in the life sciences industry.

Main Points of Discussion

  • Understanding Modular Content: Alana and Stephanie define modular content and emphasize its strategic nature rather than just a capability, highlighting the importance of people, processes, and technology.
  • Challenges in Implementation: The discussion covers the regulatory and operational hurdles that organizations face, emphasizing the need for a solid foundation and trust within teams.
  • Steps to Successful Adoption: Practical advice on building a robust digital asset management system and the importance of change readiness before diving into modular content.

Alana Goodman is the Program and Operations Lead at Decisive Consulting, with over 13 years of experience in content operations and industry consulting. She has been involved in ten product launches across various therapies and organizations. Alana is passionate about precision marketing and the impact of content in life sciences.

Stephanie Taubin is the founder and CEO of Taubin Collaborative Solutions. With a background in the ad agency world and in-house pharmaceutical operations, Stephanie focuses on operationalizing creative teams and driving efficiency through digital asset management systems. She brings extensive experience in consulting and partnering with industry experts to help clients make informed decisions.

Vodori

Part of this channel

Vodori

Faster market access through compliant life science content review.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

AL
Annalise Ludtke
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

AG
Alana Goodman

Program and Operations Lead

Decisive Consulting

Alana Goodman is the Program and Operations Lead at Decisive Consulting, with over 13 years of experience in content operations and industry consulting. She has been involved in ten product launches across various therapies and organizations. Alana is passionate about precision marketing and the impact of content in life sciences.

ST
Stephanie Taubin

Founder and CEO

Taubin Collaborative Solutions

Stephanie Taubin is the founder and CEO of Taubin Collaborative Solutions. With a background in the ad agency world and in-house pharmaceutical operations, Stephanie focuses on operationalizing creative teams and driving efficiency through digital asset management systems. She brings extensive experience in consulting and partnering with industry experts to help clients make informed decisions.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512